+

WO2007039761A3 - Structure cristalline de cd44 et son utilisation - Google Patents

Structure cristalline de cd44 et son utilisation Download PDF

Info

Publication number
WO2007039761A3
WO2007039761A3 PCT/GB2006/003734 GB2006003734W WO2007039761A3 WO 2007039761 A3 WO2007039761 A3 WO 2007039761A3 GB 2006003734 W GB2006003734 W GB 2006003734W WO 2007039761 A3 WO2007039761 A3 WO 2007039761A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystal structure
protein
pharmaceuticals
tables
interaction
Prior art date
Application number
PCT/GB2006/003734
Other languages
English (en)
Other versions
WO2007039761A2 (fr
Inventor
David G Jackson
Suneale Banerji
Martin Noble
Anthony J Day
Original Assignee
Medical Res Council
David G Jackson
Suneale Banerji
Martin Noble
Anthony J Day
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council, David G Jackson, Suneale Banerji, Martin Noble, Anthony J Day filed Critical Medical Res Council
Publication of WO2007039761A2 publication Critical patent/WO2007039761A2/fr
Publication of WO2007039761A3 publication Critical patent/WO2007039761A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne la structure cristalline de la molécule de la protéine CD44. Cette structure est présentée dans les tableaux de 1 à 4. On peut utiliser ladite structure pour modéliser l'interaction de composés, tels que des produits pharmaceutiques, avec la protéine et déterminer la structure des molécules associées.
PCT/GB2006/003734 2005-10-06 2006-10-06 Structure cristalline de cd44 et son utilisation WO2007039761A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0520365.8 2005-10-06
GBGB0520365.8A GB0520365D0 (en) 2005-10-06 2005-10-06 Crystal structure of CD44 and its use

Publications (2)

Publication Number Publication Date
WO2007039761A2 WO2007039761A2 (fr) 2007-04-12
WO2007039761A3 true WO2007039761A3 (fr) 2007-06-21

Family

ID=35429941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/003734 WO2007039761A2 (fr) 2005-10-06 2006-10-06 Structure cristalline de cd44 et son utilisation

Country Status (2)

Country Link
GB (1) GB0520365D0 (fr)
WO (1) WO2007039761A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
EP2542253A4 (fr) 2010-03-05 2013-08-21 Angstrom Pharmaceuticals Inc Modulation du signalement intracellulaire
EP4153192B8 (fr) 2020-05-19 2024-09-04 Institut Curie Antagoniste de la voie cd44/acide hyaluronique pour utilisation dans une méthode de traitement du syndrome de libération de cytokines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094843A2 (fr) * 2002-05-10 2003-11-20 Incyte Corporation Proteines d'adhesion cellulaire et a matrice extracellulaire

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094843A2 (fr) * 2002-05-10 2003-11-20 Incyte Corporation Proteines d'adhesion cellulaire et a matrice extracellulaire

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BANERJI SUNEALE ET AL: "LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 144, no. 4, 22 February 1999 (1999-02-22), pages 789 - 801, XP002159438, ISSN: 0021-9525 *
BLUNDELL T L ET AL: "HIGH-THROUGHPUT CRYSTALLOGRAPHY FOR LEAD DISCOVERY IN DRUG DESIGN", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, BASINGSTOKE, GB, vol. 1, no. 1, January 2002 (2002-01-01), pages 45 - 54, XP009023187, ISSN: 1474-1784 *
HUMPHRIES M J ET AL: "The structure of cell-adhesion molecules.", TRENDS IN CELL BIOLOGY FEB 1998, vol. 8, no. 2, February 1998 (1998-02-01), pages 78 - 83, XP009079851, ISSN: 0962-8924 *
JACKSON DAVID GERALD ET AL: "Structure of the inflammatory homing receptor CD44 complexed with its pericellular matrix ligand hyaluronan.", FASEB JOURNAL, vol. 20, no. 5, Part 2, March 2006 (2006-03-01), & EXPERIMENTAL BIOLOGY 2006 MEETING; SAN FRANCISCO, CA, USA; APRIL 01 05, 2006, pages A915, XP009079901, ISSN: 0892-6638 *
TAKEDA MITSUHIRO ET AL: "Ligand-induced structural changes of the CD44 hyaluronan-binding domain revealed by NMR.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 29 DEC 2006, vol. 281, no. 52, 29 December 2006 (2006-12-29), pages 40089 - 40095, XP002422616, ISSN: 0021-9258 *
TERIETE PETER ET AL: "Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44.", MOLECULAR CELL 27 FEB 2004, vol. 13, no. 4, 27 February 2004 (2004-02-27), pages 483 - 496, XP002422615, ISSN: 1097-2765 *

Also Published As

Publication number Publication date
WO2007039761A2 (fr) 2007-04-12
GB0520365D0 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
CO6180433A2 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
ITRM20050332A1 (it) Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
WO2008037380A3 (fr) Mélanges d'alkylbenzoates
WO2008155057A3 (fr) Mélanges d'hydrocarbures et leur utilisation
IL186543A0 (en) Solubility of cellulose in ionic liquids with addition of amino bases
IL229509A0 (en) Preparations containing chemically modified small molecules and processes using them
WO2007038138A3 (fr) Utilisation pharmaceutique de composes amido
WO2008070692A8 (fr) Composés chimiques et leurs utilisations
WO2006076594A3 (fr) Anticorps et proteines de fusion fc a immunogenicite modifiee
WO2007100412A3 (fr) Méthodes et compositions associées à la modulation de ribocommutateurs
MX2007011493A (es) Modalidades antiinflamatorias.
WO2006123051A3 (fr) Para-tertio-butylcalix[6]arenes portant des fonctions triacides en positions 2, 4 et 6 , membranes liquides supportees et materiaux supports les comportant et leurs utilisations
WO2006079057A3 (fr) Methodes et compositions pour une inhibition specifique d'un epissage proteinique, par de petites molecules
WO2006097327A3 (fr) Proteine btnl2 soluble utile pour inhiber les troubles inflammatoires
WO2005105842A3 (fr) Structure cristalline du cytochrome p450 3a4 et utilisations
WO2007039761A3 (fr) Structure cristalline de cd44 et son utilisation
WO2006089954A3 (fr) Composes permettant de stabiliser des preparations polypeptidiques de facteurs vii
WO2006113237A3 (fr) Cd39l3 et son role dans les diabetes
WO2007010285A3 (fr) Structure cristalline d'adenylate cyclase humaine soluble
WO2009026053A3 (fr) Inhibiteurs de l'interaction d'iaspp avec un partenaire de liaison d'iaspp et procédés d'utilisation
UY29756A1 (es) Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica.
WO2007144298A3 (fr) Colorant de dispersion, sa fabrication et son utilisation
ATE440832T1 (de) S-indacen- und indenoä5,6-düä1,3üdioxol-derivate und deren verwendung als komponente flüssigkristalliner mischungen
WO2008017863A3 (fr) Structure cristalline de mutants p53 et leur utilisation
WO2004078776A3 (fr) Peptides ny-eso-1 se liant aux molecules de classe ii et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06794685

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载